Experimental mRNA vaccine shows protection against multiple ebola viruses

May 22, 2026

Ti AI ṣe iroyin

An experimental mRNA vaccine has demonstrated effectiveness against three strains of Ebola virus in rodent tests. The vaccine targets Zaire, Sudan and Bundibugyo viruses. Researchers developed it amid an ongoing outbreak of Bundibugyo virus in Africa.

Yanfeng Yao and colleagues at the Wuhan Institute of Virology created the vaccine by combining mRNA sequences for glycoproteins from each virus along with a shared nucleoprotein inside a lipid nanoparticle. In tests, immunised mice gained complete protection against Zaire and Sudan viruses and strong protection against Bundibugyo. Hamsters also received full protection from Sudan virus exposure.

Awọn iroyin ti o ni ibatan

A volunteer receiving a needle-free vaccine in a lab with AI-designed virus models in the background.

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

June 05, 2026 Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Engineered phages redirect vaccine immunity to eradicate tumors in mice

Researchers have used genetically modified phages to harness pre-existing vaccine immunity and destroy cancer cells in mice. The approach eradicated tumors in 44 percent of treated animals with no recurrence after a year.

Moderna advances hantavirus vaccine after cruise ship deaths

May 11, 2026 Ti AI ṣe iroyin

Moderna confirmed ongoing work on an mRNA vaccine for hantavirus following a deadly outbreak on a Dutch cruise ship. The effort, in partnership with Korea University, began in 2023 and shows promise but remains years from completion.

Asia

Philippines remains free of Ebola, DOH says

Africa

Scientists warn of bat coronavirus risk in East Africa

Africa

WHO warns of Ebola spread risk as Kenya activates emergency response measures

Virus injection halts pancreatic tumor growth in trial

A genetically engineered virus has stopped pancreatic tumors from growing in three patients in an early US clinical trial. The results come from a safety study led by researchers at the University of Minnesota.

Scripps researchers reveal HIV and Ebola weak spots using nanodiscs

April 12, 2026 Ti AI ṣe iroyin

Scientists at Scripps Research have developed a nanodisc platform that mimics viral membranes, uncovering hidden interactions in HIV and Ebola proteins that traditional methods miss. The technology allows for more accurate study of antibody responses, potentially accelerating vaccine development. The findings appear in Nature Communications.

June 13, 2026 13:47